Intuitive Surgical stock holds above $400 as strong quarter and da Vinci growth support outlook

Intuitive Surgical Inc. (ISIN US46120E6023) stock is trading a little above the $400 mark as of August 13, 2026, following a strong recent quarter where revenue climbed double digits and earnings beat consensus, keeping the robotic surgery leader in focus for growth-oriented investors.

Stock hovers near recent highs

Market data as of the morning of August 13, 2026, show Intuitive Surgical shares trading around $400 to $402 on Nasdaq, with one snapshot citing a fair value price of $400.41 and another listing a pre-market quote of $402.82 in early trading.

Recent data compiled from quote overviews indicate that the latest completed close for Intuitive Surgical was $401.27, giving the company a market capitalization of $141.76 billion and trading volume of 3.14 million shares.

Viewed against these figures, an intraday price in the $400 region places the stock fractionally above its last close, underscoring that the shares are consolidating rather than making a pronounced move as investors digest the latest fundamentals.

Earnings beat and double-digit growth

The latest reported quarter, released in mid-July 2026, delivered robust top and bottom line growth for Intuitive Surgical.

Per one earnings recap, quarterly revenue reached $2.89 billion, rising 18.4% year over year from the prior-year quarter and surpassing analyst expectations of $2.83 billion.

On the profit side, Intuitive Surgical earned $2.80 per share in the quarter, topping consensus estimates of $2.48 and increasing sharply from $1.81 per share in the same period a year earlier.

The company also reported a net margin of 28.45% and return on equity of 16.91% for the quarter, indicating that growth is translating into healthy profitability and capital efficiency instead of coming solely from volume expansion.

Equities research projections compiled in the same overview point to full-year earnings of 8.87 per share for the current fiscal year, suggesting that the latest quarterly profit run-rate is broadly consistent with the market’s expectations for the year.

Analyst consensus continues to lean constructive, with a moderate buy stance and an average price target of $508.68 compared to recent trading close to $402, implying a double-digit percentage upside embedded in current models if the company delivers on its growth path.

Procedure growth outlook and ACA headwinds

Beyond headline numbers, Intuitive Surgical’s outlook is closely tied to growth in procedures performed on its da Vinci robotic systems.

In commentary on the second half of 2026, the company maintained its da Vinci procedure growth forecast at 13.5% to 15.5% for the full year and indicated that performance is expected to land near the midpoint of this range.

Management has warned that reported growth will face some pressure in the second half of 2026 due to tougher U.S. comparisons in the third quarter and seasonal factors in international markets.

In addition, the company is incorporating changes in patient behavior related to Affordable Care Act dynamics into its assumptions for near-term demand, which has contributed to a slowdown in U.S. procedure growth.

That said, data for the period show U.S. utilization still increasing 3% and system placements rising 24%, reinforcing that the installed base is expanding and existing systems are being used more frequently despite the temporary headwinds.

The company highlighted that concerns linked to ACA-related behavior have not yet affected its capital pipeline, which is a key indicator for future system placements and long-term revenue, and that strong adoption of the newer da Vinci 5 platform continues to support upgrades and capacity expansion.

From an investor perspective, these figures paint a nuanced picture: headline procedure growth is moderating, but underlying demand for robotic-assisted surgery remains intact, and the main risk is the duration of deferred procedures rather than a structural weakening of the business model.

Valuation, consensus, and insider selling

Despite robust growth and positive margin metrics, valuation remains an active discussion point for Intuitive Surgical stock.

One recent analysis characterizes the shares as priced for precision, reflecting the market’s willingness to pay a premium for a company with strong competitive advantages, consistent growth, and high returns on capital.

In the same context, a data-driven overview notes that Intuitive Surgical currently holds a value score assessment of D and a rank reflecting a hold stance, signaling that on traditional valuation metrics the stock screens as expensive even though its earnings trajectory is favorable.

The average analyst price target of $508.68 compared with the latest trading levels near $402.30 implies roughly a 26% upside, but this potential needs to be weighed against concerns about slowing domestic procedure growth and the risk that high expectations leave little room for disappointment.

Investors also factor insider activity into their view of valuation and future performance.

A recent insider selling disclosure shows that a company director executed a significant sale transaction in August 2026, with shares sold at prices around the low-$400 level, following the strong quarterly report.

While a single insider sale does not automatically signal a negative outlook, it often prompts market participants to revisit position sizing and consider whether the current valuation adequately reflects both the company’s growth and the operational risks it faces.

Da Vinci platform anchors growth story

Intuitive Surgical’s growth and profitability are grounded in its da Vinci robotic-assisted surgical platform.

The company’s systems enable minimally invasive procedures across multiple surgical specialties, including urology, gynecology, general surgery, and thoracic surgery, providing surgeons with enhanced precision and visualization through robotic instruments and three-dimensional imaging.

The business model combines capital equipment sales, recurring revenue from instruments and accessories used in each procedure, and service contracts that support ongoing maintenance of installed systems.

As the installed base expands and utilization rises, procedure-driven revenue tends to grow faster than system placements, creating a flywheel effect where recurring income becomes a larger share of total revenue.

The introduction of the da Vinci 5 platform adds another layer to this story by offering improved ergonomics, advanced imaging, and workflow enhancements, which can encourage existing customers to upgrade while also making the technology more attractive to new hospitals and surgical centers.

In regions where healthcare systems are under pressure to improve efficiency and patient outcomes, robotic-assisted surgery can be a compelling proposition, which supports Intuitive Surgical’s long-term outlook despite shorter-term swings in procedure growth and macroeconomic conditions.

Shares trade just above $400

For investors tracking the daily tape, Intuitive Surgical shares most recently closed at $401.27 on Nasdaq, with intraday indications on August 13, 2026, showing trading in a tight band around the $400 level.

This level sits modestly above a prior VWAP reading of $399.46 reported for August 11, 2026, where Intuitive Surgical was quoted at $401.23 with a two percent daily gain, indicating that the shares have held their ground in the low-$400s through recent sessions.

In a market environment where many growth names face scrutiny over valuation and earnings sustainability, Intuitive Surgical’s combination of an 18.4% year-over-year revenue increase to $2.89 billion, a quarterly earnings beat to $2.80 per share, and a full-year earnings projection of 8.87 per share helps explain why the stock remains supported near this level even as investors weigh ACA-related headwinds and slower U.S. procedure growth.

Read more

Further detailed disclosures on Intuitive Surgical’s financials and filings can be accessed through the company’s official SEC filings page, which lists recent forms and descriptions.

Company and stock facts

Company: Intuitive Surgical Inc.

ISIN: US46120E6023

Ticker: ISRG

Exchange: Nasdaq

Price (as of August 13, 2026, latest intraday indication): $400.41 USD

Market cap: $141.76 billion (as of the latest close)

Sector / Industry: Health care / Medical equipment and supplies

Index membership: S&P 500